UK Community Advisory Board (UK-CAB)

UK-CAB 35 – Early diagnosis and primary infection

Friday 9 July 2010

At the MRC Clinical Trials Unit, 222 Euston Road, London, NW1

09:30–10:00 Registration, refreshments and expenses
10:00–10:05 Welcome and UK-CAB updates
10:05–10.30 Pre-meeting for Merck – Simon Collins
10:30–11:15 Early diagnosis and primary infection – Prof Jonathan Weber, Faculty of Medicine at Imperial College London
11:00–11:15 Break
11.15–12.00 CASCADE study: Seroconverters Database – Kholoud Porter
12.00–12.30 Vienna preview: a guide on what to look out for; podcasts, updates from organisations, the 1st time IAC attendee – Paul Clift and Silvia Petretti
12:30–14:00 Lunch
14:00–15:30 Company meeting: Merk
15.30–15.35 Break
15:35–16.00 BHIVA feedback, UKCAB AOB
16.00 Close

Background reading

Bruce Walker abstract:
Immune Control in Chronic Human Viral Infections

Treatment in primary HIV infection

Primary Infection

Primary HIV Infection: to treat or not to treat?
Download pdf file [196 Kb]
NOTE: This is a longer and more technical report, but very interesting. One of the authors, Prof Jonathan Weber will be speaking at the meeting. The three articles above summarize this document.

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.